冠昊生物收盘上涨1.42%，滚动市盈率170.17倍，总市值47.46亿元

Company Overview - Guanhao Biological Technology Co., Ltd. focuses on developing new products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of development [2] - The main products include biological dura (spinal) membrane patches, chest repair membranes, sterile biological dressings, and corneal implants [2] - The company is recognized as a "National Intellectual Property Advantage Enterprise" and has several subsidiaries classified as high-tech enterprises [2] Financial Performance - As of the first quarter of 2025, the company reported revenue of 94.79 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, also up by 3.30% [2] - The gross profit margin stands at 77.05% [2] Market Position - The company's stock closed at 17.9 yuan, with a rolling price-to-earnings (PE) ratio of 170.17, significantly higher than the industry average of 54.79 and the median of 37.86 [1][3] - The total market capitalization is 4.746 billion yuan [1] Shareholder Information - As of July 31, 2025, the number of shareholders is 31,161, an increase of 562 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]